Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | COFO and Secretary | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,995 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 2,768 · Balance 278,995 F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. F2: Includes 135,475 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 523,749 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 523,749 F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
F2: Includes 135,475 Unvested RSUs.
F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 25,000 | $0.68 | $17,000.00 |
DisclosureSEC source: 0001714899-23-000030 · wf-form4_167650569228111.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 524,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,521 | $30.89 | $46,983.69 |
DisclosureSEC source: 0001714899-23-000020 · wf-form4_167607068513350.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 499,902 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.78 to $31.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 4,250 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-23-000018 · wf-form4_167416615634275.xml · derivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,937 Underlying: Common Stock · 10,000 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 114 | $29.87 | $3,405.18 |
DisclosureSEC source: 0001714899-23-000018 · wf-form4_167416615634275.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 497,173 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,886 | $29.53 | $291,933.58 |
DisclosureSEC source: 0001714899-23-000018 · wf-form4_167416615634275.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 497,287 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.87 to $29.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001714899-23-000018 · wf-form4_167416615634275.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 507,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 02:41 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,636 | $28.44 | $74,967.84 |
DisclosureSEC source: 0001714899-23-000014 · wf-form4_167331850392461.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 497,173 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 7,500 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,912 | $28.70 | $83,574.40 |
DisclosureSEC source: 0001209191-23-002181 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,828 F3 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.48 to $28.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 138,192 RSUs. F5 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 7,750 RSUs held by the Reporting Person. Read SEC document |
| January 04, 2023 Filed Jan 9, 2023 21:05 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,912 | $28.70 | $83,574.40 |
DisclosureSEC source: 0001209191-23-002545 · doc4a.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 492,309 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.48 to $28.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 7,750 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 123,360 | $0.00 Strike: $27.63 | $0.00 |
DisclosureSEC source: 0001209191-23-002181 · doc4.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,360 Underlying: Common Stock · 123,360 shares Expires 2033-01-02 F7 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2024, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 41,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002181 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,578 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2024 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 138,192 RSUs. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 20:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-22-000135 · wf-form4_166560511822999.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,078 Underlying: Common Stock · 20,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting of the shares subject to the option is contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on the date the closing price of Issuer's Common Stock equaled or exceeded $40.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018; and 50% of the shares subject to the option vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 20:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 20,000 | $0.68 | $13,600.00 |
DisclosureSEC source: 0001714899-22-000135 · wf-form4_166560511822999.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 487,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:46 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,576 | $33.22 | $85,574.72 |
DisclosureSEC source: 0001714899-22-000127 · wf-form4_166128759380161.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 467,471 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.11 to $33.38 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Schuth Family 2017 Trust in connection with the vesting of 5,000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 23:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000124 · wf-form4_166026004225336.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,458 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on August 9, 2023 (the"Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a serviceprovider of the Issuer through each such date. F2 · balance_after: Includes 109,822 restricted stock units. F3 · balance_after: Includes 540 shares acquired under the ESPP Purchase on May 31, 2022. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 23:55 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,803 | $34.68 | $97,208.04 |
DisclosureSEC source: 0001714899-22-000040 · wf-form4_164496930840504.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 465,047 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.42 to $35.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Schuth Family 2017 Trust in connection with the vesting of 7,286 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,423 | $37.10 | $52,799.70 |
DisclosureSEC source: 0001714899-22-000034 · wf-form4_164461787567236.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 460,564 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.71 to $37.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Schuth Family 2017 Trust in connection with the vesting of 4250 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 23:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,846 | $44.77 | $127,415.42 |
DisclosureSEC source: 0001714899-22-000005 · wf-form4_164159671916562.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 457,737 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.44 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Schuth Family 2017 Trust in connection with the vesting of 7500 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000004 · wf-form4_164142742987933.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2032-01-02 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2023, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000004 · wf-form4_164142742987933.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,454 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 106,358 restricted stock units. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,200 | $42.45 | $305,640.00 |
DisclosureSEC source: 0001714899-21-000116 · wf-form4_163900292998153.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,083 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $42.21 to $42.91 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,800 | $41.82 | $117,096.00 |
DisclosureSEC source: 0001714899-21-000116 · wf-form4_163900292998153.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 460,283 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $41.16 to $42.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,283 | $53.23 | $174,754.09 |
DisclosureSEC source: 0001714899-21-000107 · wf-form4_163640615125307.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 463,083 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $52.94 to $53.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,717 | $52.65 | $353,650.05 |
DisclosureSEC source: 0001714899-21-000107 · wf-form4_163640615125307.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 466,366 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $51.93 to $52.88 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 22:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,006 | $51.04 | $204,466.24 |
DisclosureSEC source: 0001714899-21-000094 · wf-form4_163355842818926.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 473,083 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.64 to $51.3350 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Restated to accurately report holdings that were misallocated in the Reporting Person's previous Form 4. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 22:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,994 | $50.24 | $301,138.56 |
DisclosureSEC source: 0001714899-21-000094 · wf-form4_163355842818926.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 477,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.6350 to $50.6275 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Restated to accurately report holdings that were misallocated in the Reporting Person's previous Form 4. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 9,045 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-21-000092 · wf-form4_163234839118824.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,078 Underlying: Common Stock · 9,045 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The vesting of the shares subject to the option is contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on the date the closing price of Issuer's Common Stock equaled or exceeded $40.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018; and 50% of the shares subject to the option vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 22:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 9,045 | $0.68 | $6,150.60 |
DisclosureSEC source: 0001714899-21-000092 · wf-form4_163234839118824.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,441 | $56.05 | $136,818.05 |
DisclosureSEC source: 0001714899-21-000090 · wf-form4_163122171523267.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 474,038 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.00 to $56.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,350 | $55.67 | $297,834.50 |
DisclosureSEC source: 0001714899-21-000090 · wf-form4_163122171523267.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 476,479 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.01 to $55.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,209 | $54.70 | $120,832.30 |
DisclosureSEC source: 0001714899-21-000090 · wf-form4_163122171523267.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 481,829 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.01 to $55.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 196 | $50.10 | $9,819.60 |
DisclosureSEC source: 0001714899-21-000086 · wf-form4_162976470516097.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 484,038 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.08 to $50.12 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,348 | $49.56 | $116,366.88 |
DisclosureSEC source: 0001714899-21-000086 · wf-form4_162976470516097.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 484,234 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.08 to $50.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Schuth Family 2017 Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 200 | $52.99 | $10,598.00 |
DisclosureSEC source: 0001714899-21-000082 · wf-form4_162828056411896.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 481,582 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,236 | $52.34 | $431,064.00 |
DisclosureSEC source: 0001714899-21-000082 · wf-form4_162828056411896.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 481,782 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.93 to $52.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 04, 2021 Filed Aug 6, 2021 20:09 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,564 | $51.52 | $80,571.02 |
DisclosureSEC source: 0001714899-21-000082 · wf-form4_162828056411896.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 490,018 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.93 to $51.92 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,000 | $76.20 | $762,040.00 |
DisclosureSEC source: 0001209191-21-045986 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 491,582 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.68 to $76.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,340 | $64.82 | $281,301.44 |
DisclosureSEC source: 0001209191-21-038977 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 501,582 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.70 to $64.91 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,660 | $64.35 | $364,198.36 |
DisclosureSEC source: 0001209191-21-038977 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 505,922 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.70 to $64.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 445 | $57.39 | $25,538.55 |
DisclosureSEC source: 0001209191-21-030724 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 511,582 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.80 to $57.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,557 | $55.92 | $198,889.66 |
DisclosureSEC source: 0001209191-21-030724 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 512,027 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.55 to $56.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,998 | $55.09 | $330,435.82 |
DisclosureSEC source: 0001209191-21-030724 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 515,584 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.52 to $55.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 00:39 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 700 | $57.44 | $40,205.90 |
DisclosureSEC source: 0001209191-21-025768 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 521,582 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.11 to $57.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 00:39 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,156 | $56.47 | $234,668.54 |
DisclosureSEC source: 0001209191-21-025768 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 522,282 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.10 to $57.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 00:39 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,144 | $55.60 | $286,026.98 |
DisclosureSEC source: 0001209191-21-025768 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 526,438 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.10 to $56.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| March 04, 2021 Filed Mar 4, 2021 23:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,878 | $61.58 | $115,647.24 |
DisclosureSEC source: 0001209191-21-017983 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 531,582 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.375 to $62.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| March 04, 2021 Filed Mar 4, 2021 23:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,122 | $60.89 | $494,524.21 |
DisclosureSEC source: 0001209191-21-017983 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 533,460 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.37 to $61.325 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 433 | $71.41 | $30,919.66 |
DisclosureSEC source: 0001209191-21-011008 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 541,582 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.87 to $71.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 7,285 shares acquired pursuant to vesting of restricted stock units and issued directly to the Schuth Family Trust U/A DTD 06/05/2017. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,614 | $70.17 | $183,421.77 |
DisclosureSEC source: 0001209191-21-011008 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 542,015 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.80 to $70.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 7,285 shares acquired pursuant to vesting of restricted stock units and issued directly to the Schuth Family Trust U/A DTD 06/05/2017. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 206 | $75.68 | $15,590.90 |
DisclosureSEC source: 0001209191-21-009892 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 537,344 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.22 to $76.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.